Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Significant Decrease in Short Interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 376,288 shares, a drop of 16.8% from the March 15th total of 452,420 shares. Currently, 8.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 37,885 shares, the days-to-cover ratio is presently 9.9 days.

Hedge Funds Weigh In On Coeptis Therapeutics

Several hedge funds have recently bought and sold shares of COEP. Steward Partners Investment Advisory LLC raised its holdings in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after purchasing an additional 2,500 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics in the third quarter valued at $140,000. Marshall Wace LLP purchased a new position in shares of Coeptis Therapeutics in the fourth quarter valued at $259,000. State Street Corp increased its position in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the last quarter. 13.88% of the stock is owned by hedge funds and other institutional investors.

Coeptis Therapeutics Stock Up 6.9%

Shares of NASDAQ COEP opened at $14.65 on Friday. The stock has a market capitalization of $91.12 million, a price-to-earnings ratio of -4.92 and a beta of -0.44. Coeptis Therapeutics has a 52 week low of $6.26 and a 52 week high of $21.41. The firm has a 50-day moving average price of $11.91 and a 200 day moving average price of $13.97. The company has a quick ratio of 4.16, a current ratio of 4.16 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:COEP) last issued its earnings results on Thursday, March 19th. The company reported ($0.12) earnings per share for the quarter. Coeptis Therapeutics had a negative return on equity of 110.89% and a negative net margin of 803.96%.The company had revenue of $0.86 million for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Coeptis Therapeutics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Coeptis Therapeutics presently has a consensus rating of “Sell”.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.